|
Press Releases |
|
 |
|
Friday, August 16, 2024 |
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
Tuesday, August 6, 2024 |
|
康哲药业:甲氨蝶呤注射液增加类风湿关节炎适应症中国NDA获批(更正版) |
康哲药业控股有限公司(“本公司”,连同其附属公司统称为“本集团”或“康哲药业”)欣然宣布,甲氨蝶呤注射液(“产品”)增加适应症的上市许可申请(NDA)已于2024年7月30日获得国家药品监督管理局(NMPA)批准。 more info >> |
|
康哲藥業:甲氨蝶呤注射液增加類風濕關節炎適應症中國NDA獲批 |
康哲藥業控股有限公司(“本公司”,連同其附屬公司統稱為“本集團”或“康哲藥業”)欣然宣佈,甲氨蝶呤注射液(“產品”)增加適應症的上市許可申請(NDA)已於2024年7月30日獲得國家藥品監督管理局(NMPA)批准。 more info >> |
|
Monday, August 5, 2024 |
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
Tuesday, July 16, 2024 |
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
Tuesday, June 25, 2024 |
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
GoDaddy Airo: An AI-Powered Revolutionary Solution for Asian Entrepreneurs and Small Business Owners
Feb 18, 2025 15:18 HKT/SGT
|
|
|
General Atomics and EDGE Establish Partnership to Manufacture, Test and Repair Electromechanical Systems
Feb 18, 2025 14:27 HKT/SGT
|
|
|
Osaka Gas and MHI Launch CO2NNEX Digital Platform for Management and Transfer of Clean Gas Certificates for e-Methane, for Use during Expo 2025
Feb 18, 2025 13:18 JST
|
|
|
GTJAI Assisted iMotion Automotive Technology (1274.HK) in Completing the Placing of New H Shares
Feb 18, 2025 12:15 HKT/SGT
|
|
|
國泰君安國際助力知行汽車科技(1274.HK) 完成港股配售
Feb 18, 2025 12:08 HKT/SGT
|
|
|
国泰君安国际助力知行汽车科技(1274.HK) 完成港股配售
Feb 18, 2025 12:02 HKT/SGT
|
|
|
大阪ガスと三菱重工、e-methaneのクリーンガス証書移転・管理を可能とするデジタルプラットフォーム「CO₂NNEX」の大阪・関西万博での導入に向けた運用開始について
Feb 18, 2025 11:30: JST
|
|
|
GenAI Summit Tour Lands in Manila to Redefine AI in Enterprise & Government
Feb 18, 2025 10:00: JST
|
|
|
Hola Prime Now Offers Immediate Funding with Instant Account
Feb 18, 2025 10:00: JST
|
|
|
Cybersecurity Leaders to Convene at the 2025 Cyber Resilience Summit Delivering Competitive Advantage Through Security
Feb 18, 2025 09:00: JST
|
|
|
GenAI Summit Tour Lands in Manila to Redefine AI in Enterprise & Government
Feb 18, 2025 09:00 HKT/SGT
|
|
|
Hola Prime Now Offers Immediate Funding with Instant Account
Feb 18, 2025 09:00 HKT/SGT
|
|
|
Move Digital Announces Strategic Expansion into Robotics Manufacturing
Feb 18, 2025 09:00: JST
|
|
|
Cybersecurity Leaders to Convene at the 2025 Cyber Resilience Summit Delivering Competitive Advantage Through Security
Feb 18, 2025 08:00 HKT/SGT
|
|
|
Move Digital Announces Strategic Expansion into Robotics Manufacturing
Feb 18, 2025 08:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|